Ovarian cancer patients' and their family members' perspectives on novel vaccine and virotherapy trials

Carmen Radecki Breitkopf, Jennifer L. Ridgeway, Gladys B. Asiedu, Katherine Carroll, Meaghan Tenney, Aminah Jatoi

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background/aims: Some of the most promising avenues of cancer clinical investigation center on immunotherapeutic approaches. These approaches have provided notable gains in cancer therapeutics with recent Food and Drug Administration approvals of agents of this class in several types of cancers, although gains for ovarian cancer lag behind. This study examined perceptions of therapeutic trials including immunotherapy and virotherapy among ovarian cancer patients and their family members. Methods: A total of 72 semi-structured qualitative interviews were conducted with 33 patients and 39 family members at two National Cancer Institute-designated comprehensive cancer centers. Eligible patients were diagnosed with epithelial ovarian, primary peritoneal, or fallopian tube carcinoma and had experience with clinical trial conversations; family members were nominated by patients and interviewed separately. Applied thematic analysis was used to understand and interpret the data. Results: More participants were aware of vaccine trials than virus trials, although more than half had heard of at least one of them. Initial reactions to vaccine trials were generally favorable. For many, childhood experience with vaccines lent a familiar frame of reference. Virus trials elicited more negative initial reactions, including the use of adjectives such as "scary" and "dreadful." Viruses seemed contagious or difficult to control. Increased receptivity to these trials occurred in the context of limited therapeutic options and cancer recurrence. Most participants, including those not immediately drawn to these types of trials, indicated openness to learning more. Conclusion: Although vaccine and viral trials are both immunologically based therapeutic approaches, patients who are offered these trials may perceive their potential benefit and safety quite differently. There is a need to consider terminology, solicit and address "gut reactions," and provide information that enables patients and their family members to better understand the science behind these trials.

Original languageEnglish (US)
Pages (from-to)660-664
Number of pages5
JournalClinical Trials
Volume13
Issue number6
DOIs
StatePublished - Dec 1 2016

Fingerprint

Ovarian Neoplasms
Vaccines
Neoplasms
Viruses
Viral Vaccines
Drug Approval
Fallopian Tubes
National Cancer Institute (U.S.)
United States Food and Drug Administration
Therapeutics
Terminology
Immunotherapy
Clinical Trials
Learning
Interviews
Carcinoma
Safety
Recurrence

Keywords

  • clinical trials
  • immunotherapy
  • Ovarian cancer
  • qualitative

ASJC Scopus subject areas

  • Medicine(all)
  • Pharmacology

Cite this

Ovarian cancer patients' and their family members' perspectives on novel vaccine and virotherapy trials. / Radecki Breitkopf, Carmen; Ridgeway, Jennifer L.; Asiedu, Gladys B.; Carroll, Katherine; Tenney, Meaghan; Jatoi, Aminah.

In: Clinical Trials, Vol. 13, No. 6, 01.12.2016, p. 660-664.

Research output: Contribution to journalArticle

Radecki Breitkopf, Carmen ; Ridgeway, Jennifer L. ; Asiedu, Gladys B. ; Carroll, Katherine ; Tenney, Meaghan ; Jatoi, Aminah. / Ovarian cancer patients' and their family members' perspectives on novel vaccine and virotherapy trials. In: Clinical Trials. 2016 ; Vol. 13, No. 6. pp. 660-664.
@article{7779d21a4af94390991b0a4cea2908b9,
title = "Ovarian cancer patients' and their family members' perspectives on novel vaccine and virotherapy trials",
abstract = "Background/aims: Some of the most promising avenues of cancer clinical investigation center on immunotherapeutic approaches. These approaches have provided notable gains in cancer therapeutics with recent Food and Drug Administration approvals of agents of this class in several types of cancers, although gains for ovarian cancer lag behind. This study examined perceptions of therapeutic trials including immunotherapy and virotherapy among ovarian cancer patients and their family members. Methods: A total of 72 semi-structured qualitative interviews were conducted with 33 patients and 39 family members at two National Cancer Institute-designated comprehensive cancer centers. Eligible patients were diagnosed with epithelial ovarian, primary peritoneal, or fallopian tube carcinoma and had experience with clinical trial conversations; family members were nominated by patients and interviewed separately. Applied thematic analysis was used to understand and interpret the data. Results: More participants were aware of vaccine trials than virus trials, although more than half had heard of at least one of them. Initial reactions to vaccine trials were generally favorable. For many, childhood experience with vaccines lent a familiar frame of reference. Virus trials elicited more negative initial reactions, including the use of adjectives such as {"}scary{"} and {"}dreadful.{"} Viruses seemed contagious or difficult to control. Increased receptivity to these trials occurred in the context of limited therapeutic options and cancer recurrence. Most participants, including those not immediately drawn to these types of trials, indicated openness to learning more. Conclusion: Although vaccine and viral trials are both immunologically based therapeutic approaches, patients who are offered these trials may perceive their potential benefit and safety quite differently. There is a need to consider terminology, solicit and address {"}gut reactions,{"} and provide information that enables patients and their family members to better understand the science behind these trials.",
keywords = "clinical trials, immunotherapy, Ovarian cancer, qualitative",
author = "{Radecki Breitkopf}, Carmen and Ridgeway, {Jennifer L.} and Asiedu, {Gladys B.} and Katherine Carroll and Meaghan Tenney and Aminah Jatoi",
year = "2016",
month = "12",
day = "1",
doi = "10.1177/1740774516654445",
language = "English (US)",
volume = "13",
pages = "660--664",
journal = "Clinical Trials",
issn = "1740-7745",
publisher = "SAGE Publications Ltd",
number = "6",

}

TY - JOUR

T1 - Ovarian cancer patients' and their family members' perspectives on novel vaccine and virotherapy trials

AU - Radecki Breitkopf, Carmen

AU - Ridgeway, Jennifer L.

AU - Asiedu, Gladys B.

AU - Carroll, Katherine

AU - Tenney, Meaghan

AU - Jatoi, Aminah

PY - 2016/12/1

Y1 - 2016/12/1

N2 - Background/aims: Some of the most promising avenues of cancer clinical investigation center on immunotherapeutic approaches. These approaches have provided notable gains in cancer therapeutics with recent Food and Drug Administration approvals of agents of this class in several types of cancers, although gains for ovarian cancer lag behind. This study examined perceptions of therapeutic trials including immunotherapy and virotherapy among ovarian cancer patients and their family members. Methods: A total of 72 semi-structured qualitative interviews were conducted with 33 patients and 39 family members at two National Cancer Institute-designated comprehensive cancer centers. Eligible patients were diagnosed with epithelial ovarian, primary peritoneal, or fallopian tube carcinoma and had experience with clinical trial conversations; family members were nominated by patients and interviewed separately. Applied thematic analysis was used to understand and interpret the data. Results: More participants were aware of vaccine trials than virus trials, although more than half had heard of at least one of them. Initial reactions to vaccine trials were generally favorable. For many, childhood experience with vaccines lent a familiar frame of reference. Virus trials elicited more negative initial reactions, including the use of adjectives such as "scary" and "dreadful." Viruses seemed contagious or difficult to control. Increased receptivity to these trials occurred in the context of limited therapeutic options and cancer recurrence. Most participants, including those not immediately drawn to these types of trials, indicated openness to learning more. Conclusion: Although vaccine and viral trials are both immunologically based therapeutic approaches, patients who are offered these trials may perceive their potential benefit and safety quite differently. There is a need to consider terminology, solicit and address "gut reactions," and provide information that enables patients and their family members to better understand the science behind these trials.

AB - Background/aims: Some of the most promising avenues of cancer clinical investigation center on immunotherapeutic approaches. These approaches have provided notable gains in cancer therapeutics with recent Food and Drug Administration approvals of agents of this class in several types of cancers, although gains for ovarian cancer lag behind. This study examined perceptions of therapeutic trials including immunotherapy and virotherapy among ovarian cancer patients and their family members. Methods: A total of 72 semi-structured qualitative interviews were conducted with 33 patients and 39 family members at two National Cancer Institute-designated comprehensive cancer centers. Eligible patients were diagnosed with epithelial ovarian, primary peritoneal, or fallopian tube carcinoma and had experience with clinical trial conversations; family members were nominated by patients and interviewed separately. Applied thematic analysis was used to understand and interpret the data. Results: More participants were aware of vaccine trials than virus trials, although more than half had heard of at least one of them. Initial reactions to vaccine trials were generally favorable. For many, childhood experience with vaccines lent a familiar frame of reference. Virus trials elicited more negative initial reactions, including the use of adjectives such as "scary" and "dreadful." Viruses seemed contagious or difficult to control. Increased receptivity to these trials occurred in the context of limited therapeutic options and cancer recurrence. Most participants, including those not immediately drawn to these types of trials, indicated openness to learning more. Conclusion: Although vaccine and viral trials are both immunologically based therapeutic approaches, patients who are offered these trials may perceive their potential benefit and safety quite differently. There is a need to consider terminology, solicit and address "gut reactions," and provide information that enables patients and their family members to better understand the science behind these trials.

KW - clinical trials

KW - immunotherapy

KW - Ovarian cancer

KW - qualitative

UR - http://www.scopus.com/inward/record.url?scp=85000982076&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85000982076&partnerID=8YFLogxK

U2 - 10.1177/1740774516654445

DO - 10.1177/1740774516654445

M3 - Article

VL - 13

SP - 660

EP - 664

JO - Clinical Trials

JF - Clinical Trials

SN - 1740-7745

IS - 6

ER -